Key Segmentation:
By Drug Class
-
GABA Agonists
-
Botulinum Toxins
-
Alpha-2 Adrenergic Agonists
-
Benzodiazepines
-
Dantrolene Sodium
-
Other Drug Classes
By Indication
-
Multiple Sclerosis
-
Cerebral Palsy
-
Stroke
-
Spinal Cord Injury
-
Traumatic Brain Injury
-
Other Indications
By Route of Administration
-
Oral
-
Parenteral
-
Intrathecal
By Patient Age Group
-
Adults
-
Pediatrics
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Drug Class X Indication)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
Key players include AbbVie Inc. (Allergan), Ipsen S.A., Merz Therapeutics GmbH, Medtronic plc, and Teva Pharmaceutical Industries Ltd., among others.
Key opportunities include pediatric label extensions for neurotoxins, novel gene and cannabinoid-based therapies, and expanding neurology and rehabilitation infrastructure across Asia-Pacific and Latin America.
The primary growth factor is the rising global burden of stroke, multiple sclerosis, and cerebral palsy, combined with growing adoption of targeted botulinum toxin and intrathecal baclofen therapies.
By drug class, the GABA Agonists segment dominates the Spasticity Drugs Market with approximately 38.46% share in 2025.
North America dominates the Spasticity Drugs Market with approximately 41.62% share in 2025.